Related Experiment Video
Updated: Dec 4, 2025
A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis
Published on: March 9, 2015
Hair Loss in Patients Treated with Vismodegib: A Single-Center Retrospective Study
Alessia Villani1, Gabriella Fabbrocini1, Claudia Costa1
1Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Abstract:
Locally advanced basal cell carcinoma had always represented a form of skin cancer which had been difficult to treat until the hedgehog inhibitor vismodegib was approved. This small molecule acts by inhibiting the hedgehog signaling pathway that plays a critical role in the process of tumorigenesis. Although several trials have demonstrated the high efficacy of this drug, different adverse events have been described. Muscle spasms, dysgeusia, weight loss, and alopecia are the adverse events most frequently reported. The objective of this study was to report the incidence of alopecia arising in patients treated with vismodegib, assessing its characteristics, grade of severity, and time of onset.
Insights
Vismodegib effectively treats advanced basal cell carcinoma by inhibiting the hedgehog pathway. This study details the incidence, characteristics, and onset of alopecia, a common side effect of this cancer treatment.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Locally advanced basal cell carcinoma (BCC) presents significant treatment challenges.
- Hedgehog pathway inhibitors, such as vismodegib, have emerged as effective therapies for BCC.
- Adverse events are associated with vismodegib treatment, necessitating further characterization.
Purpose of the Study:
- To investigate the incidence of alopecia in patients receiving vismodegib for BCC.
- To assess the specific characteristics, severity, and onset timing of vismodegib-induced alopecia.
Main Methods:
- Retrospective analysis of patients treated with vismodegib.
- Documentation of alopecia occurrence, grading, and temporal relationship to treatment initiation.
Main Results:
- Alopecia is a frequently reported adverse event in patients treated with vismodegib.
- Detailed incidence rates, severity grades, and onset patterns of alopecia were observed.
- The study provides quantitative data on the prevalence and timeline of this side effect.
Conclusions:
- Vismodegib is an effective treatment for advanced BCC, but alopecia is a notable adverse event.
- Understanding the incidence and characteristics of alopecia is crucial for patient management and counseling.
- Further research may explore the mechanisms and management strategies for vismodegib-induced alopecia.
